Indication: Pulmonary Arterial Hypertension
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension
Sub-indication: Pulmonary Arterial Hypertension (PAH)
Study Type: Drug Study
Principal Investigator: John McConnell, M.D.Norton Pulmonary Specialists
Sponsor: Sponsor: Merck Sharp & Dohme CORP